advertisement
Abstract #54434 Published in IGR 15-3
Topical glaucoma therapy cost in Mexico
Lazcano-Gomez G; Hernandez-Oteyza A; Iriarte-Barbosa MJ; Hernandez-Garciadiego CInternational Ophthalmology 2014; 34: 241-249
Glaucoma is an important cause of irreversible blindness that represents a significant economic burden; most direct costs of glaucoma are drug-related. We calculated the annual cost of some of the most commonly prescribed glaucoma medications in Mexico, according to their average wholesale price (AWP) and dose regimen. Annual costs ranged from USD4.97 for Imot 15 ml (timolol 0.5 %; Laboratorios Sophia) to USD675.39 for Alphagan 5 ml (brimonidine 0.2 %; Allergan, Inc.). β-Blockers were the least expensive glaucoma medications (range USD20.44-55.44). Alphagan 5 ml was 250 % more expensive than other selective α2-agonists. Of the carbonic anhydrase inhibitors, dorzolamide 2 % was less expensive than brinzolamide 1 % (USD326.91 vs. USD418.96). The annual cost for prostaglandin analogs ranged from USD235.58 for bimatoprost 0.03 % to USD337.78 for latanoprost 0.005 %. Some fixed combinations were less expensive than separate combinations. The average annual cost for all treatments increased by 27.87 ± 10.09 % between 2009 and 2012. Annual glaucoma therapy cost seems to be lower in Mexico than in other countries, due to a lower AWP, especially for some medications made by Mexican laboratories.
Asociación Para Evitar la Ceguera en México, I.A.P., Vicente Gacía Torres 46, Barrio San Lucas, CP 04030, Mexico, DF, Mexico.
Full articleClassification:
14 Costing studies; pharmacoeconomics
